Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Andreas Gloger has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, LAFAVE, ELIZABETH ROSE, who is the busiest examiner for the company with 1 pending office action. The prosecution is occurring within 1 distinct art unit.
With only 1 pending office action, the company's current patent prosecution is limited to a single matter. The involvement of only 1 distinct examiner and 1 distinct art unit suggests a narrow technical focus. LAFAVE, ELIZABETH ROSE is the sole point of contact for the company's active prosecution at this time.
The concentration of the workload under a single examiner suggests a streamlined prosecution process. Because there is only 1 busiest examiner pending action, the technical focus of the examination remains narrow. Practitioners working with LAFAVE, ELIZABETH ROSE will find that this individual manages the entirety of the company's currently pending work. This structure allows for a very specific legal strategy tailored to the preferences of a single examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LAFAVE, ELIZABETH ROSE | 1 | 64.4% | +43.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18032513 | SELF-PURIFIED NUCLEIC ACID ENCODED LIBRARIES | LAFAVE, ELIZABETH ROSE | — |
| Art Unit | Apps |
|---|---|
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18032513 | SELF-PURIFIED NUCLEIC ACID ENCODED LIBRARIES | LAFAVE, ELIZABETH ROSE | 1684 | §102 | Non-Final OA | — | Pending | Apr 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAndreas Gloger has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Elizabeth Rose Lafave has the most, with 1 of Andreas Gloger's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
